The Competition Commission of India (CCI) has approved the US$3.2 billion merger of Sun Pharmaceuticals with Ranbaxy Laboratories, which was announced in April.
The combined entity would have operations in 65 countries, 47 manufacturing facilities across five continents and a wide array of specialty and generic products marketed globally.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
